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Adiponectin differentially affects gene expression in human
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Serum levels of adiponectin are inversely associated with breast cancer risk. In this study, its effect on growth and gene expression of
MCF-7 breast cancer cells and MCF-10A human mammary epithelial cells was compared. The antiproliferative effect of adiponectin
on MCF-10A cells was more pronounced and was accompanied by elevated transcript levels of caspase 1, ERb2, ERb5, TR2 and
USP2. Our data suggest that upregulation of genes with known growth inhibitory or apoptotic functions in mammary epithelial cells
might contribute to the protective action of this adipocytokine.
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Adipose tissue acts as an endocrine organ secreting a variety of
proteins into the blood known as adipocytokines (Matsuzawa et al,
1999). In contrast to other adipocytokines, serum adiponectin
concentration is inversely correlated with obesity (Abbasi et al,
2004). Low serum adiponectin levels were shown to serve as a
significant risk factor for breast cancer, particularly in postmeno-
pausal women (Miyoshi et al, 2003).
In this study, we examined the molecular mechanisms under-
lying the antitumoural action of adiponectin. For this purpose, we
studied adiponectin-triggered changes in the oestrogen receptor
expression and attempted to identify other genes regulated by this
adipocytokine in MCF-7 breast cancer cells and in MCF-10A-
immortalised human mammary epithelial cells.
MATERIALS AND METHODS
Materials
Full-length low-weight adiponectin expressed in insect H5 cells as
recently described (Neumeier et al, 2006) was kindly provided by
Christa Bu ¨chler, Department of Internal Medicine I, University of
Regensburg. Serum replacement 2 (SR2) was obtained from Sigma
(Deisenhofen, Germany). RNeasy Mini Kit, RNase Free DNase Set
and Quantitect SYBR Green PCR Kit were obtained from Qiagen
(Hilden, Germany).
Cell culture and proliferation assay
MCF-7 (HTB-22) breast cancer cells and MCF-10A-immortalised
breast epithelial cells (ATCC, Manassas, VA, USA) were main-
tained in DMEM/F12 medium containing 10% fetal calf serum
(FCS), supplemented with 0.01mgml
 1 insulin and 1mM sodium
pyruvate (MCF-7) or with 1nM epidermal growth factor (EGF)
(MCF-10A) and cultured with 5% CO2 at 371C in a humidified
incubator. For analysis of adiponectin effects on cell growth, both
cell lines were serum starved and cultured in DMEM/F12 contain-
ing 1  SR2. Cells were seeded in 96-well plates in triplicate
(2500 cells per well) and were treated with 10mgml
 1 full-length
adiponectin. After 0, 3, 4, 5 and 6 days, relative numbers of viable
cells were measured in comparison with the untreated control
using the fluorimetrical, resazurin-based Cell Titer Blue assay
(Promega, Mannheim, Germany) according to the manufacturer’s
instructions at 560Ex/590Emnm in a Victor3 multilabel counter
(PerkinElmer, Massachusetts, USA). Cell growth was expressed as
a percentage of the untreated medium control. Statistical analysis
of the data was performed by one-way ANOVA using Prism
2.0 Software (GraphPad, San Diego, CA, USA), with statistical
significance accepted at Po0.05.
RNA preparation and hybridisation of DNA microarrays
Total RNA was isolated by means of the RNeasy kit (Qiagen)
according to the manufacturer’s instructions. After DNAse
treatment and subsequent precipitation, 20mg of total RNA was
used for cDNA synthesis using a cDNA kit (Roche, Mannheim,
Germany). After purification of the cDNA, Cy3- and Cy5-labelled
cRNA were generated using the MEGAscriptt T7 Kit (Ambion,
Woodward, USA). After purification of the labelled cRNA using the
High Pure RNA Tissue Kit (Roche) and its fragmentation, 10mgo f
Cy3- and Cy5-labelled cRNA were used for the hybridisation of the
human 10k-A array (MWG Biotech, Ebersberg, Germany) containing
oligonucleotides that represent approximately 10000 human genes
with known functions. The measurement of the slides was
performed by the scanning service of MWG Biotech. Data are
presented as a relationship between gene expression in untreated
MCF-7 or MCF-10A cells (defined as 100%) and the respective
expression 48h after treatment with 10mgml
 1 adiponectin.
Reverse transcription and real-time PCR
From 1mg of total RNA, cDNA was synthesised using 100U
M-MLV-P reverse transcriptase (Promega), 2.5mM dNTP mixture
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sand 50pM random primers (Invitrogen, Karlsruhe, Germany). All
PCR primers were designed intron-spanning to avoid amplifica-
tion of genomic DNA; primer sequences are indicated in Table 1.
For real-time PCR analysis, 4ml of 1:5 diluted cDNA was amplified
using the Quantitect SYBR Green PCR Kit (Qiagen) and
the LightCycler PCR device (Roche Diagnostics, Mannheim,
Germany). The PCR programme was 951C for 10min, followed
by 40 PCR cycles (951C for 10s, 581C for 10s, 721C for 15s) and a
final extension for 5min at 721C, followed by a standard melting
curve analysis. In all RT–PCR experiments, a 190bp b-actin
fragment was amplified as a reference gene using intron-spanning
primers. After testing that the efficiencies of all primer pairs were
approximately equal (Stahlberg et al, 2003), data were analysed
using the comparative DDCT method (Livak and Schmittgen, 2001)
by calculating the difference between the threshold cycle (CT)
values of the target and reference gene of each sample and then
comparing the resulting DCT values among different samples.
RESULTS
As a pre-requirement for this study, we first tested the expression
of adiponectin receptors (AdipoR) 1 and 2 in the cell lines used. By
means of real-time RT–PCR, we detected notable amounts of both
transcripts in MCF-7 and MCF-10A cells (Figure 1). Receptor
mRNA levels were in a similar range in both cell lines (data not
shown).
The effect of a physiological concentration of adiponectin on
growth of MCF-7 and MCF-10A cells was tested in serum-free,
defined culture medium and assessed over a cultivation period of 6
days. Adiponectin significantly inhibited the growth of MCF-10A
mammary epithelial cells, but not of MCF-7 breast cancer cells. In
relation to the untreated control, this effect was significant after
4 or more days, with a maximum growth reduction by 30% evident
after 5 days (Figure 2).
A total of six 10k DNA microarrays (MWG, Martinsried,
Germany) were used to analyse adiponectin effects on gene
expression. Total RNA was isolated from MCF-7 and MCF-10A
cells cultured in serum-free, defined culture medium treated with
adiponectin (10mgml
 1) for 48h. Microarray data confirmed by 2-
fold repetition of the experiment including dye swap revealed a
more than 5-fold increase of transcript levels of caspase 1 (CASP1)
(5.94-fold), TR2 orphan nuclear hormone receptor (6.31-fold) and
ubiquitin-specific peptidase 2 (USP2) (5.37-fold) in MCF-10A cells.
These effects were not observed in microarray experiments
comparing the transcriptome of MCF-7 cells before and after
adiponectin treatment (Table 2).
More than 5-fold expression changes after adiponectin treat-
ment observed in the microarray experiments in case of the genes
CASP1, TR2 and USP2 were now confirmed by means of RT–PCR.
Table 1 Sequences of the PCR primers used in this study
AdipoR1 50-GGGGAATTCTCTTCCCACAAAGGATCTGTGGTG-30
50-GGGCTGCAGTTAAGTTTCTGTATGAATGCGGAAGAT-30
AdipoR2 50-GGGGAATTCAACGAGCCAACAGAAAACCGATTG-30
50-GGGCTGCAGCTAAATGTTGCCTGTTTCTGTGTGTAT-30
ERa 50-TGATGAAAGGTGGGATACGA-30
50-AAGGTTGGCAGCTCTCATGT-30
ERb15 0-TTTGGGTGATTGCCAAGAGC-30
50-AGCACGTGGGCATTCAGC-30
ERb25 0-CCCAGAGGGAAACTGAAGTG-30
50-AACCTCCTGATGCTCCTGTC-30
ERb55 0-CACTTTTCCCAAATCACTTCACC-30
50-TTTGGGTGATTGCCAAGAGC-30
USP2 50-CATCCAGAGGTTCCCAAAGA-30
50-CCAGGTCTCTTAGGGGGAAG-30
CASP1 50-TCTTCCTTTCCAGCTCCTCA-30
50-CTGCCGACTTTTGTTTCCAT-30
TR2 50-CACAACACCTGCAGCTCCTA-30
50-TGACGTCCTGATGCTTTGTC-30
b-actin 50-CTGTGGCATCCACGAAACTA-30
50-CGCTCAGGAGGAGCAATG-30
200 bp -
500 bp -
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Figure 1 Expression of adiponectin receptors (AdipoR) 1 and 2 in
MCF-7 and MCF-10A cells detected by means of RT–PCR. After real-time
RT–PCR analysis (35 cycles, LightCycler, Roche), PCR products were
subjected to 1.5% agarose gel electrophoresis.
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Figure 2 The effect of adiponectin (10mgml
 1) on growth of MCF-7
and MCF-10A cells over a cultivation time of 6 days. Data are expressed in
percentage of the untreated control (n¼3). *Po0.05 vs untreated control.
Table 2 Gene expression changes detected by means of microarray
analysis (10k-A array, MWG Biotech, Martinsried, Germany) in MCF-7
breast cancer cells and MCF-10A mammary epithelial cells after treatment
with adiponectin (NS¼not significant) (n¼3 including dye swap)
MCF-10A MCF-7
GENE Factor Factor
TR2 6.31 NS
CASP1 5.94 NS
USP2 5.37 NS
ZNF235 4.49 NS
SERPINB13 3.67 NS
MGST2 3.40 NS
RNF130 3.28 NS
SLC25A20 0.22 NS
DDX59 NS 4.17
GIMAP5 NS 3.64
NRG1 NS 3.22
PSCD3 NS 0.27
Microarray analysis based on ANOVA was performed and the cut off value was a
3-fold difference.
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sIncreased levels of these genes in adiponectin-treated MCF-10A
cells were also detected by means of real-time RT–PCR, although
this increase was only 2.5-fold in case of TR2 and USP2 (Figure 3).
Given that our recent results suggested interactions between
oestrogen receptor (ER) and adiponectin signalling (Pfeiler et al,
2008), adiponectin effects on expression of ERa and ERb-isoforms
were also examined in these RT–PCR experiments. In MCF-10A
cells, we observed a more than 5-fold increase of ERb2 and an
approximately 2-fold increase of ERb5 mRNA levels after
adiponectin treatment. As expected from our microarray data,
adiponectin did not trigger elevated transcript levels of TR2,
CASP1 and USP2 in MCF-7 breast cancer cells, but a significantly
reduced USP2 expression by approximately 60%. Similar to the
mammary epithelial cell line, in MCF-7 cells ERb2 mRNA levels
were also upregulated by more than 5-fold after adiponectin
treatment.
DISCUSSION
Adiponectin levels are inversely related to the prognostic factors of
breast cancer (Miyoshi et al, 2003; Mantzoros et al, 2004).
Furthermore, direct antitumoural effects of adiponectin such as
inhibition of proliferation have been reported from in vitro studies
(Kang et al, 2005, 2007; Nakayama et al, 2007). These observations
suggested that adiponectin might be able to protect from breast
cancer development. In this study, we examined the effects of
adiponectin on proliferation and gene expression of immortalised
mammary epithelial cells in comparison with breast cancer cells.
Recently, expression of both AdipoR was reported to be present
in various benign mammary epithelial and breast cancer cell lines
(Takahata et al, 2007). In this study, mRNA levels of AdipoR1 and
AdipoR2 were shown to be expressed in a similar range in MCF-7
and MCF-10A cells. However, treatment with adiponectin exerted
different effects on these cell lines. Physiological concentrations of
this adipocytokine significantly slowed down the proliferation of
MCF-10A mammary epithelial cells, but not of MCF-7 breast
cancer cells. The results of earlier studies examining the effect of
adiponectin on MCF-7 breast cancer cells are contradictory. Our
group and others had earlier reported the absence of adiponectin
effects on the growth of MCF-7 breast cancer cells (Kang et al,
2005; Pfeiler et al, 2008). Although some studies reported small
apoptotic effects of adiponectin on this cell line not significantly
affecting the total cell numbers (Arditi et al, 2007; Grossmann et al,
2008), in another study, growth-inhibitory effects on MCF-7 cells
were observed (Dieudonne et al, 2006). However, this incon-
sistency might result from different experimental conditions used
in the studies mentioned. In an earlier study, an antiproliferative
effect of adiponectin on MCF-7 cells was not present under serum-
free culture conditions as used in this study and was suggested to
be dependent on the presence of steroid hormones such as 17-b
estradiol (Pfeiler et al, 2008).
To our knowledge, this is the first study demonstrating a
significant growth inhibitory effect of adiponectin on mammary
epithelial cells. This observation might reveal at least one
mechanism underlying the association between high adiponectin
serum levels and reduced breast cancer risk. It is tempting to
speculate that adiponectin might be able to exert protective effects
on mammary epithelial cells. The lack of any antiproliferative
effect on MCF-7 breast cancer cells suggests that adiponectin-
triggered growth control might be lost during carcinogenesis.
Given that MCF-7 cells expressed AdipoR to a similar extent, the
molecular mechanisms of this different response remained to be
elucidated.
Given that earlier data of our group suggested the presence of a
cross talk between adiponectin and oestrogen signalling systems
(Pfeiler et al, 2008), we first analysed the effect of an adiponectin
treatment on ERa and b expression. In MCF-10A cells, adiponectin
triggered a significant increase of ERb2 and ERb5 mRNA levels.
ERb is the dominant oestrogen receptor in normal breast tissue
(Speirs et al, 2000, 2002; Shaw et al, 2002), but its expression
declines during tumorigenesis (Leygue et al, 1998; Roger et al,
2001). This study and a variety of in vitro studies of our group and
others suggested a role for ERb as a tumour suppressor in breast
tissue (Skliris et al, 2003; Treeck et al, 2008). ERb2 and ERb5
proteins both are known to form heterodimers with ERa, thereby
inhibiting the transcriptional activity of ERa (Peng et al, 2003). As
ERa is known to mediate tumour-promoting effects of 17-b
estradiol, our data suggest that adiponectin-triggered increase of
ERb isoform expression might be one important molecular
mechanism underlying the protective effects of this adipocytokine.
This seems to be particularly true for ERb5 splice variant, as the
expression of this isoform was exclusively increased in MCF-10A
cells.
Then, we studied the gene expression changes triggered by
adiponectin in MCF-7 and MCF-10A cells by means of DNA
microarrays. After treatment with adiponectin, in MCF-10A
mammary epithelial cells, we observed elevated transcript levels
of several genes known to exert antitumoural effects in breast
tissue.
Adiponectin treatment led to increased transcript levels of TR2
orphan nuclear hormone receptor in MCF-10A, but not in MCF-7
cells. Recent results of in vitro studies of cultured cells ectopically
expressing TR2 suggested potential roles for TR2 in a variety of
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Figure 3 RT–PCR analysis of the adiponectin effects on gene expression in MCF-10A mammary epithelial cells and MCF-7 breast cancer cells. Grey bars
represent gene expression after 48h of treatment with adiponectin (10mgml
 1). Data are expressed in percentage of untreated control (black bars, defined
as 100%). *Po0.05 vs untreated control.
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tional activity of ERa, leading to enhanced proliferation of breast
epithelial cells and to tumour progression, can be inhibited not
only by ERb, but also by TR2. Furthermore, TR2-siRNA was
reported to enhance ERa-dependent proliferation of MCF-7 cells
(Hu et al, 2002). Our data suggest that adiponectin-triggered
increase of TR2 expression could also lead to the suppression of
ERa-mediated proliferation in mammary epithelial cells, thereby
exerting protective, antitumoural effects.
TR2 has also been reported to be upregulated during apoptotic
processes and its overexpression resulted in an increased apoptosis
rate (Lee and Wei, 2000). It is tempting to speculate that
adiponectin-triggered increase of TR2 might be able to confer an
increased apoptotic potential to mammary epithelial cells, thereby
also exerting protective effects.
In MCF-10A mammary epithelial cells treated with adiponectin,
we also found a significant increase of USP2 mRNA levels, but a
decrease in MCF-7 breast cancer cells. In breast cancer, an enhanced
activity of the ubiquitin–proteasome system has been reported
(Deng et al, 2007). However, the exact role of USP in breast tissue
remains unknown. Ubiquitination may be a candidate for either a
tumour-suppressive or an oncogenic activity (Fujiwara et al, 1998).
Adiponectin treatment of MCF-10A cells also resulted in
elevated transcript levels of CASP1 , a key enzyme of apoptosis.
This effect again was not observed in MCF-7 breast cancer cells.
Our data suggest that adiponectin-triggered increase of CASP1
expression might be another molecular mechanism underlying the
antitumoural effect of this adipocytokine, which is present in
mammary epithelial cells, but has been lost in MCF-7 breast cancer
cells. Adiponectin-triggered activation of caspase expression has
also been reported from endothelial cells, resulting in decreased
angiogenesis (Brakenhielm et al, 2004). Given that decreased
neovascularisation exerts antitumoural effects, the antiangio-
genetic effect of this adipocytokine mediated by CASP1 upregulation
might be another mechanism underlying the inverse association
between adiponectin serum levels and breast cancer risk.
In this study, we observed an adiponectin-triggered growth
inhibition of MCF-10A cells accompanied by specific upregulation
of genes with known antitumoural properties. Our data suggest
that adiponectin might be able to exert protective effects on
mammary epithelial cells only, whereas MCF-7 breast cancer cells
might have lost the ability to respond to this adipocytokine in a
similar manner.
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